1. Question 1  What is our Global Ranking for DM ?  What is our current estimated burden?  Why is T2DM so important ?

Slides:



Advertisements
Similar presentations
Oral Hypoglycemic Drugs And Classifications
Advertisements

Managing T2DM during Ramadan Dr. Asrar Said Hashem Specialist in Internal Medicine (Al-Amiri Hospital) Fellow of KIMS Endocrine, Diabetes and Metabolism.
DM & CKD Dr. Shahrzad Shahidi Professor of Nephrology Isfahan University of Medical Sciences.
Diabetes (abridged!). Who needs screening for DM? Age >45 Obese – BMI >25 1 st degree relative with DM Racial groups: –African American –Hispanic American.
Glucose Tolerance Test Diabetes Mellitus Dr. David Gee FCSN Nutrition Assessment Laboratory.
Type 2 Diabetes Mellitus Aetiology, Pathogenesis, History, and Treatment.
Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
Oral Medications to Treat Type 2 Diabetes
Combination Therapy in Type 2 Diabetes
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
The Diagnosis of Diabetes Mellitus
Barriers to Diabetes Control Mark E. Molitch, MD.
Oral Glucose Tolerance Test By: Dr. Beenish Zaki Date: 09/05/2012 Senior Instructor Department of Biochemistry.
What is Diabetes?.
1. DIABETIC NEPHROPATHY Dr. Shahrzad Shahidi 2 CLASSIFICATION 1. Type 1 (due to b-cell destruction, usually leading to absolute insulin deficiency) 2.
LONG TERM BENEFITS OF ORAL AGENTS
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
Drugs used in Diabetes Dr Sally Hudson. BIGUANIDES reduce output of glucose from the liver and enhances uptake and use of glucose by muscle cells ExampleADVANTAGESDISADVANTAGESCOSTCaution.
Criteria for Diagnosis of DM * Testing must be repeated on separate day. FPG is the preferred test ** Symptoms of DM IFG = Impaired fasting glucose IGT.
Diabetes Mellitus Ibrahim Sales, Pharm.D. Assistant Professor of Clinical Pharmacy King Saud University
Chapter 24 Chapter 24 Exercise Management.  Diabetes is a chronic metabolic disease characterized by an absolute or relative deficiency of insulin that.
Epidemiology of Diabetes Mellitus by Santi Martini Departemen of Epidemiology Faculty of Public Health University of Airlangga.
TREAT TO TARGET IN DIABETES: An Alternative pathway
DIABETES AND HYPOGLYCEMIA. What is Diabetes Mellitus? “STARVATION IN A SEA OF PLENTY”
Diabetes Mellitus (Lecture 2). Type 2 DM 90% of diabetics (in USA) Develops gradually may be without obvious symptoms may be detected by routine screening.
Criteria for the diagnosis of DM Symptoms of diabetes plus random blood glucose concentration ≥ 200 mg/dl OR FPG ≥ 126 mg/dl OR Two –hour plasma glucose.
oral hypoglycemic agents
Oral Hypoglycemic Drugs
Diabetes: The Modern Epidemic Roy Buchinsky, MD Director of Wellness.
DIABETES MELLITUS Management. IMPORTANT POINTS: IN HISTORY, EXAMINATION, INVESTIGATIONS AND TREATMENT –Control: good / poor? Treatment? –Complications.
Reem Sallam, MD, MSc. PhD Clinical Chemistry Unit, Pathology Dept. College of Medicine, King Saud University.
Dr. Amr S. Moustafa, MD, PhD Clinical Chemistry Unit, Pathology Dept. College of Medicine, King Saud University.
Chronic Disease Management- Diabetes. 43 year old male presents with one month history of feeling very thirsty and hungry. Urinating 5 times every night.
Oral hypoglycemic drugs Prof. Mohammad Alhumayyd.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Clinical Practice Glycemic Management of Type 2 Diabetes Mellitus Faramarz Ismail-Beigi, M.D., Ph.D. Dr.kalantar N Engl J Med Volume 366(14):
January 2013 Webinar: “Practical Ways to Help Get Our Diabetes Patients to Goal” Controlling the ABC’s Cases.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
Epidemiology and Diagnosis A Practical Guide to Therapy Monotherapy Combination Therapy Add ons.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & Early DM Part 5 Stan Schwartz MD, FACP, FACE.
 Provide a high level overview of diabetes head to toe.  Discuss the importance of keeping A1Cs under 8.  Identify ways to prevent long-term complications.
Hypoglycemia & Hyperglycemia Dave Joffe, BSPharm, CDE, FACA.
SGLT-2 Inhibitors Surprising New Information. Logic for SGLT-2 Inhibition : My Own Comment on MOA- Logic for Benefit: 1.Kidney is an ‘active player’ in.
Who?16 Million Americans (6% of pop’n) (only about 2/3 are diagnosed) 7% of Americans have Impaired Fasting Glucose (IFG; >110-
JULY 8 TH 2010 Good Morning!. Risk Factors Obesity Positive Family History Specific Ethnic Groups Gender Conditions with Insulin Resistance  Puberty.
Dixie L. Thompson chapter 20 Exercise and Diabetes.
Diabetes Mellitus Introduction to Diabetes Epidemiology.
Oral Diabetes Medications Carol Cordy, MD. Goals Understand how type 2 diabetes affects many organs and how this changes over the course of the illness.
Chapter Exercise and Diabetes Dixie L. Thompson C H A P T E R.
Who is considered elderly? “Young old” years “Old, old” >75 years.
Diabetic Profile Measurement of Blood Glucose T.A. Bahiya Osrah.
Diabetes. Objectives: Diabetes Mellitus (DM) Discuss the prevalence of diabetes in the U.S. Contrast the main types of diabetes. Describe the classic.
Dr. Mansour Alzahrani. متى اكتشف داء السكري؟ داء السكري في الحضارة الهندية والصينية القديمة اسهامات علماء المسلمين في داء السكري.
นพ. เฉลิมศักดิ์ สุวิชัย โรงพยาบาล พะเยา. Management of Type 2 Diabetes Mellitus: A New Paradigm Approach Dr. Chalermsak Suwichai Phayao Hospital.
DM- ANSWERS TO CASES 1&2. ANSWERS 1. How did the insulin deficiency lead to an increase in plasma glucose & ketone conc.? Insulin is responsible for shifting.
What is Diabetes? Definition: A disorder of metabolism where the pancreas produces little or no insulin or the cells do not respond to the insulin produced.
Dr. Sasan Zaeri (PharmD, PhD) Department of Pharmacology, BPUMS.
DIABETES MELLITUS. Diabetes mellitus (DM) is a metabolic disorder resulting from a defect in insulin secretion, insulin action, or both. DM is associated.
Dr. Sasan Zaeri (PharmD, PhD) Department of Pharmacology, BPUMS
Estimation of blood glucose in diabetes mellitus
Metabolic Changes in Diabetes Mellitus
Lecture on Anti Diabetic Drugs
Metabolic Changes in Diabetes Mellitus
Metabolic Changes in Diabetes Mellitus
Diabetes Health Status Report
Macrovascular Complications Microvascular Complications
oral hypoglycemic agents
Diabetes Dr. J. Antony Gagnon, Pharm.D., CDE, CAE
Diabetes.
Presentation transcript:

1

Question 1  What is our Global Ranking for DM ?  What is our current estimated burden?  Why is T2DM so important ?

Question 1  What is our Global Ranking for DM ?  What is our current estimated burden?  Why is T2DM so important ?  Numero Uno – RANK ONE Globally  About 36 million (in 2003)  DM = CAD + Its major complications !!  Shortens longevity by years

Question 2  What are the TWO major defects in Type 2 Diabetes ?

Question 2  What are the TWO major defects in Type 2 Diabetes ?  Insulin Resistance (IR)  Insulin Deficiency (ID)

Question 3  What is  cell apoptosis ?   cell apoptosis occurs in how many years ?

Question 3  What is  cell apoptosis ?   cell apoptosis occurs in how many years ?  Progressive programmed  cell death  10 to 15 years after the onset of DM  Today’s approach is save the  cell

Question 4  What are the core defects of Insulin Secretion in T2DM ?

Question 4  What are the core defects of Insulin Secretion in T2DM ?  Loss or delay of first phase of Insulin secretion  Blunting or flattening of second phase

Question 5  What is Gold Standard Test to Diagnose DM ?  Should we use Plasma Sugar or Whole blood Sugar for Diagnosis ?

Question 5  What is Gold Standard Test to Diagnose DM ?  Should we use Plasma Sugar or Whole blood Sugar for Diagnosis ?  O-GTT – Fasting sample and 2 hours Post Glucose (75g) sample  Obviously Plasma (venous sample)

Question 6  What is Normal FBG & What is IFG ?  What is Normal PPBG & What is IGT ?  Is it essential two have TWO readings ?

Question 6  What is Normal FBG & What is IFG ?  What is Normal PPBG & What is IGT ?  Is it essential two have TWO readings ?  N =100 mg FBG; is IFG  N =140 mg PPBG; is IGT  YES – Two readings are a must for Dx.  FBG  126 or PPBG  200 is DM

Question 7  Can we use urine sugar for Dx. or F/u ?  Can we use HbA1c for Diagnosis ?  What is important in urine exam in DM ?

Question 7  Can we use urine sugar for Dx. or F/u ?  Can we use HbA1c for Diagnosis ?  What is important in urine exam in DM ?  No. Urine sugar is not all useful  No. HbA1c is not for Diagnosis; only F/u  Albumin, MAU, Ketones are very imp.

Question 8  What is the cause of Fasting Hyperglycemia ?  What is the defect that causes it ?

Question 8  What is the cause of Fasting Hyperglycemia ?  What is the defect that causes it ?  Increase in Hepatic Glucose Output – Called HGO  Decrease in Basal Insulin secretion

Question 9  What is the cause of Postprandial Hyperglycemia ?  What is the defect that causes it ?

Question 9  What is the cause of Postprandial Hyperglycemia ?  What is the defect that causes it ?  Decrease in peripheral utilization – removal of glucose by muscle & adipose tissue  Excess CHO meal load  Delay or absence of 1 st Phase Insulin

Question 10  What are the four mechanisms which contribute to ↑ plasma glucose ?

Question 10  What are the four mechanisms which contribute to ↑ plasma glucose ? 1.Hepatic Glucose Output (HGO) Basal In 2.Lack of peripheral utilization (IR) 3.Decrease in insulin secretion (ID) 4.Increase in absorption from GIT

Question 11  What is HbA1c ?  What is its normal value ?  What does it reflect ?

Question 11  What is HbA1c ?  What is its normal value ?  What does it reflect ?  It is a Glycated hemoglobin  Normal HbA1c is around 6%  It represents the mean plasma glucose over the previous 120 days

Question 12  What is the best measure to monitor glycemic control for follow up ?  What is its target value ?

Question 12  What is the best measure to monitor glycemic control for follow up ?  What is its target value ?  HbA1c is the measure for monitoring  It must be kept below 7, preferably 6

Question 13  What is IDRS ?  What are its components ?

Question 13  What is IDRS ?  What are its components ?  Indian Diabetic Risk Score is used to assess ones risk for DM  Age, WC, family h/o, physical activity

Question 14  Can we prevent Diabetes ?  If so, How ?

Question 14  Can we prevent Diabetes ?  If so, How ? Yes. 3 international studied confirmed it 1.Identifying people in stage 1- IR 2.Total Lifestyle Change – MNT, PA 3.If necessary Metformin, Acarbose

Question 15  Where can we find all info on TLC ?

Question 15  Where can we find all info on TLC ? 

Question 16  What is the ‘Old Paradigm’ of Diabetes management ?

Question 16  What is the ‘Old Paradigm’ of Diabetes management ?  It is called the ‘Step Care’ approach  It envisages Diet  OAD  Insulin

Question 17  What is the ‘New Paradigm’ of Diabetes management ?

Question 17  What is the ‘New Paradigm’ of Diabetes management ?  It is the ‘Stage Management’ approach  Stage 1 – Insulin Resistance (IR)  Stage 2 – IR + Insulin Deficiency (ID)  Stage 3 – Insulin Deficiency (ID)

Question 18  What is total metabolic control ?

Question 18  What is total metabolic control ?  Glycemic control is essential but we also need to control all components  We must maintain the B.P <130/80  The lipids under target values  See that pt. avoids smoking  Reduce his weight and waist  This is total METABOLIC CONTROL

Question 19  List the microvascular complications

Question 19  List the microvascular complications 1.Diabetic Retinopathy (DR) 2.Diabetic Kidney Disease (DKD) – Nephropathy 3.Diabetic Neuropathy – DPN, DAN These start right at the onset of ↑ BG We must screen for and prevent them

Question 20  List the macrovascular complications

Question 20  List the macrovascular complications 1.Coronary Artery Disease - CAD 2.Cerebro Vascular Disease, TIA 3.Peripheral Vascular Disease PVD These start right at the onset of IR We must screen for and prevent them

Question 21  How do we identify persons with IR ?

Question 21  How do we identify persons with IR ? 1.IGT or IFG 2.WC > 36 (32) BMI > 23 3.B.P > 140/90 4.Dyslipidemia –TG>150, HDL<40(50) 5.Acanthosis Nigricans 6.Fasting C-Peptide levels increased

Question 22  What is C-Peptide ?

Question 22  What is C-Peptide ? 1.When proinsulin is cleaved into active Insulin, C-peptide is formed 2.It is measured in the fasting serum 3.It reflects the endogenous insulin secretion by  cells 4.It is used in HOMA IR model

Question 23  What are the ABC of Diabetes ?

Question 23  What are the ABC of Diabetes ? 1.A1c target of < 7% 2.B.P  130/80 3.Cholesterols  TG 40(50), Lp(a) <25

Question 24  What are the 4 major classes of OAD ?

Question 24  What are the 4 major classes of OAD ? Those  That decrease HGO - Metformin  Improve insulin Resistance - Met, TZD  Stimulate  cell – SU, Repaglinide  Slow absorption of CHO - Acarbose

Question 25  Which OAD is the sheet anchor of Diabetes treatment ?

Question 25  Which OAD is the sheet anchor of Diabetes treatment ?  Metformin in all 3 stages  Not SU – it is only in stage 2 (IR+ID)  Not Glitazone – It is not 1 st line drug

Question 26  What is the relative efficacy of OAD in terms of the glucose lowering potency ?

Question 26  What is the relative efficacy of OAD in terms of the glucose lowering potency ? 1.Metformin and SU –HbA1c ↓ 1.5% 2.Pio and Rosi – HbA1c ↓ 1.0% 3.Acarbose – HbA1c ↓ 0.5%

Question 27  What are the cut-off levels of HbA1c to make treatment decisions ?

Question 27  What are the cut-off levels of HbA1c to make treatment decisions ? 1.HbA1c of 9 or above straight away consider Insulin 2.HbA1c of < 9 to 7 consider OAD 3.HbA1c of < 7 – TLC only + Follow up

Question 28  What are the key contraindications of OAD ?

Question 28  What are the key contraindications of OAD ? 1.ALD – Met, SU, TZD 2.Renal Insufficiency – Met, SU 3.CHF, edema – TZD, Metformin 4.IBD, ALD – Acarbose 5.Pregnancy – All OADs 6.Age > 80 – Metformin, Glibenclamide

Question 29  What are the key side effects of Rx. ?

Question 29  What are the key side effects of Rx. ? 1.Metformin – GI side effects, Lactic Acidosis 2.SU – Hypoglycemia, allergy, weight gain 3.TZD – Weight gain, edema, abn. LFT 4.Acarbose – Flatulence, GI side effects 5.Insulin – Weight gain, Hypoglycemia

Question 30  Which are the best SU ?

Question 30  Which are the best SU ? In the order of superiority  Glimepiride  Gliclazide  Glipizide  Not Glibenclamide

Question 31  Which Glitazone is preferable ? Why ?

Question 31  Which Glitazone is preferable ? Why ?  Both Rosi and Pio are equally good  Slight differences in their lipid effects  Choice is individualized

Question 31  Which Glitazone is preferable ? Why ?  Pioglitazone – because it is 1.Lipid favourable 2.Comparatively less costlier 3.Of once daily dosage

Question 32  What is the difference between Analog insulins and conventional insulins ?

Question 32  What is the difference between Analog insulins and conventional insulins ? 1.Precise onset of action 2.No need to give 30’ before a meal 3.Highly predictable duration 4.Predictable absorption kinetics 5.Smaller dose sufficient (70%) 6.But costly 2 to 3 times

Question 33  What medicines are must for all Diabetics to prevent CAD ?

Question 33  What medicines are must for all Diabetics to prevent CAD ? 1.Aspirin daily 100 mg o.d. 2.Atorvastatin – min of 10 mg or equivalent 3.ACEi or ARB to protect kidney and heart 4.Adequate control of B.P and Lipids

Question 34  What is the take home message ?

Question 34  What is the take home message ? 1.Diabetes is mainly asymptomatic (80%) 2.Not screening for DM is a Deadly SIN 3.Only 70 % of diabetics are detected 4.Less than 20% are under < 7% HbA1c 5.The A, B, C, D, E must be kept in mind always and targets must be achieved 6.Early use of insulin is essential for this

1